Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences Inc.

www.gilead.com

Latest From Gilead Sciences Inc.

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

In A Record Year For US FDA Approvals, Pfizer Came Out On Top

FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders. 
Approvals Drug Review

J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds

Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.

Deals Financing

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
Commercial Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register